Skip to main content
Log in

Switching from Turbuhaler to Spiromax cost saving

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2015 euros

Reference

  • Lewis A, et al. Budesonide + formoterol delivered via Spiromax(R) for the management of asthma and COPD: The potential impact on unscheduled healthcare costs of improving inhalation technique compared with Turbuhaler(R). Respiratory Medicine 129: 179-188, Aug 2017. Available from: URL: http://doi.org/10.1016/j.rmed.2017.06.018

    Article  CAS  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Switching from Turbuhaler to Spiromax cost saving. PharmacoEcon Outcomes News 784, 27 (2017). https://doi.org/10.1007/s40274-017-4238-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4238-7

Navigation